In this week’s Trade To Black Podcast, TDR Founder Shadd Dales, lead financial writer Benjamin A. Smith and TDR contributor Anthony Varrell give their macro outlook in the cannabis, crypto and psychedelic sectors—the latter boosted early year on the promise of regulatory approval of services (MDMA).

As sentiment in the U.S. cannabis sector remains dour following anticipated regulatory reform hit a snafu in Congress, psychedelics stocks have taken an opposite turn so far in 2023. Buoyed by regulatory prospects of its own, investors have waded back in, with drug developers and clinic therapy providers receiving similar attention. Particular for the latter, sentiment has remained elevated following significant news from the Multidisciplinary Association for Psychedelic Studies (MAPS) clinical research program, which achieved an …

Full story available on Benzinga.com